ALK and non-small cell lung carcinoma: 1.1.Brigatinib indications funded by SNS in Spain, according to EMA Data Sheet:SNS indication #1: Brigatinib monotherapy is indicated for the treatment of adult patients with advanced ALK-positive NSCLC who have not been previously treated with an ALK tyrosine kinase inhibitor (TKI) [12]:Clinical evidence approval SNS indication #1: Phase III randomized study ALTA-1L (NCT02737501) evaluating efficacy and safety of brigatinib in patients with ALK-positive NSCLC who had not received prior treatment with an ALK TKI.